Explore

Sacituzumab Tirumotecan Shows Sustained Overall Survival Benefit in Advanced Triple-Negative Breast Cancer

Sacituzumab Tirumotecan Shows Sustained Overall Survival Benefit in Advanced Triple-Negative Breast Cancer

The OptiTROP-Breast01 trial, a multicenter, randomized, open-label, phase 3 study, has provided further evidence supporting sacituzumab tirumotecan (sac-TMT) as an effective treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Led by Binghe Xu, MD, PhD, from the National Cancer Center in Beijing, China, the trial enrolled 263 patients who had undergone at least two prior systemic therapies. Patients were randomized to receive either sac-TMT or single-agent chemotherapy. The final overall survival (OS) analysis, with a median follow-up of 29.4 months, demonstrated a median OS of 14.7 months for the sac-TMT group compared to 9.9 months for the chemotherapy group. This represents a significant improvement, with a hazard ratio of 0.60. The 30-month OS rates were 26.8% for sac-TMT and 13.2% for chemotherapy. The OS benefit was observed across all subgroups, including those who previously received a PD-(L)1 inhibitor and those with HER2-low tumors. The saf...

Dr. Elaine Jaffe Honored for Revolutionizing Lymphoma Pathology with Molecular Insights

Dr. Elaine Jaffe Honored for Revolutionizing Lymphoma Pathology with Molecular Insights

Dr. Elaine S. Jaffe, an NIH Distinguished Investigator and Head of the NCI Hematopathology Section, is set to receive the Award for Excellence in Molecular Diagnostics at the 2026 Association for Molecular Pathology (AMP) meeting in Seattle. This award recognizes her five decades of work that transformed lymphoma pathology from a field primarily based on microscopic appearance to one heavily informed by molecular profiling. Her career highlights include the discovery that follicular lymphoma and histiocytic sarcoma, seemingly distinct tumors, can arise from the same malignant clone, challenging fundamental assumptions about cellular identity. Jaffe's approach emphasizes pursuing unexpected clinical observations through molecular investigation to improve disease classification and patient care, demonstrating a 'Bedside to Bench' methodology.

Jim Fitterling gives AHN Cancer Center $25 million

Jim Fitterling gives AHN Cancer Center $25 million

A $25 million gift to AHN will support cancer vaccines, T-cell immunotherapy, clinical trials and expanded patient navigation.

Tempus AI to Present Six Abstracts on Precision Oncology Research at CTOS 2026 Annual Meeting

Tempus AI to Present Six Abstracts on Precision Oncology Research at CTOS 2026 Annual Meeting

Tempus AI, a company specializing in molecular profiling, artificial intelligence, and clinical data analysis, is scheduled to present six abstracts at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting in Seoul, South Korea, from November 18–21. These presentations will include three oral presentations. The research focuses on various aspects of precision oncology, particularly in rare cancers like sarcomas and gastrointestinal stromal tumors (GIST). Studies will examine molecular biomarkers, tumor classification, treatment response, and genetic alterations. One study will investigate melanoma-associated antigen A4 (MAGE-A4) messenger RNA (mRNA) expression and the tumor immune microenvironment as potential biomarkers in sarcoma. Two other studies will focus on GIST, identifying a DNA damage response (DDR) transcriptional signature and classifying GIST into prognostic risk groups using transcriptomic profiling. Additional research will cover transcriptional programs associated with pazopanib...

Moderna-Merck Personalized mRNA Melanoma Vaccine Reduces Recurrence Risk by 42% in Late-Stage Trial

Moderna-Merck Personalized mRNA Melanoma Vaccine Reduces Recurrence Risk by 42% in Late-Stage Trial

A personalized mRNA melanoma vaccine developed by Moderna and Merck has demonstrated significant efficacy in a Phase 3 clinical trial. The INTerpath-001 trial involved patients with stage IIB-IV melanoma that had been completely removed. When administered in combination with Keytruda, the vaccine, known as intismeran autogene, reduced the risk of cancer recurrence or death by 42%. After a median follow-up of 24.6 months, 82.2% of patients receiving the vaccine plus Keytruda remained free of recurrence or death, compared to 70.0% of those treated with Keytruda alone. This represents a 12.2-percentage-point difference. The benefit of the vaccine became more pronounced after the initial six months of treatment, showing a 58% lower risk of recurrence or death in a pre-specified analysis. Serious side effects (grade 3 or higher) were observed in 23.6% of the combination group and 20.3% of the control group. The overall survival data are still being evaluated.

Guardant Health Expands Liquid Biopsy Capabilities with AI and Epigenomics for Cancer Treatment

Guardant Health Expands Liquid Biopsy Capabilities with AI and Epigenomics for Cancer Treatment

Guardant Health has introduced new applications for its Guardant360 Liquid test, significantly expanding its capabilities for treatment selection in advanced breast and lung cancers. These advancements integrate genomics, epigenomics, and artificial intelligence (AI) through the InfinityAI platform to provide a more comprehensive view of tumor biology. The expanded test now includes two epigenomic predictors designed to identify patients who may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer or immune checkpoint inhibitor monotherapy in advanced non-small cell lung cancer (NSCLC). Notably, the lung cancer application can epigenomically identify PD-L1 negative patients without requiring a tissue sample, combining tumor microenvironment characterization with tumor mutational burden and microsatellite instability for immunotherapy assessment. Additionally, these new features can detect ALK fusions and MTAP deletions that genomic liquid testing alone might miss, offering d...

AACR Conference Addresses Cancer Health Disparities with Focus on Actionable Solutions

AACR Conference Addresses Cancer Health Disparities with Focus on Actionable Solutions

The 19th AACR Conference on the Science of Cancer Health Disparities, held from October 18-21, focused on identifying and implementing actionable solutions to address persistent inequities in cancer care. Monica L. Baskin, PhD, Director and Jeanette and Eric Lipman Chair in Oncology of the VCU Massey Comprehensive Cancer Center, emphasized that while significant progress has been made in cancer screening, treatment, and prevention since the National Cancer Institute's establishment in 1937, these advancements have not benefited all populations equally. The conference highlighted strategies such as community health worker programs, which have proven cost-effective in increasing screening rates for breast, cervical, and colorectal cancers. Additionally, the importance of ensuring underrepresented populations participate in clinical trials was stressed, with Baskin noting their willingness to participate if asked. The discussion also touched upon the potential of artificial intelligence (AI) to identify regio...

City of Hope Receives $11 Million Gift to Advance Personalized Cancer Treatment and AI Research

City of Hope Receives $11 Million Gift to Advance Personalized Cancer Treatment and AI Research

City of Hope, a prominent cancer research and treatment organization in the United States, has been granted an $11 million philanthropic gift from the Simms/Mann Family Foundation. This substantial donation is earmarked to accelerate research in personalized cancer prevention, diagnosis, and treatment. The investment will specifically support advancements in genomics, artificial intelligence (AI), and microbiome science. A key outcome of this gift will be the establishment of the Simms/Mann Family Foundation Precision Oncology Program in Southern California, creating a permanent funding source for high-priority research projects and emerging scientific opportunities. Additionally, the gift will fund two endowed academic chairs: one for cancer microbiome research and another for clinical cancer genomics, with the latter to be filled through a recruitment process.

UICC Launches Grants for Implementation Research on Women’s Cancers to Reduce Inequities

UICC Launches Grants for Implementation Research on Women’s Cancers to Reduce Inequities

The Union for International Cancer Control (UICC) has launched a competitive call for grants to support implementation research on women’s cancers. This initiative aims to generate practical evidence that can strengthen the delivery of proven interventions for women’s cancers, specifically breast and cervical cancer, and help reduce inequities in care. These cancers account for approximately three million new cases and one million deaths globally each year, with a disproportionate burden falling on low- and middle-income countries (LMICs), where nearly 65% of these deaths occur. Despite the availability of cost-effective, evidence-based interventions for prevention, early detection, diagnosis, treatment, and palliative care, significant gaps in implementation persist due to barriers like limited service integration, inequitable access, low uptake of services, and health system constraints. The grants seek to support civil society organizations and other eligible entities in generating context-specific insi...

Congressman André Carson Introduces Bipartisan Legislation for National Strategy on Young Adult Cancers

Congressman André Carson Introduces Bipartisan Legislation for National Strategy on Young Adult Cancers

Congressman André Carson (D-Ind.) has introduced bipartisan House legislation aimed at creating the first national strategy to address cancers in adults aged 18 to 49. The bill, named the Asal Sayas National Strategy on Young Adult Cancers Act, was co-sponsored by Representative Rob Wittman (R-Va.). This initiative seeks to direct the National Institutes of Health (NIH) to develop a comprehensive plan within 18 months of the bill becoming law. The strategy would involve mapping current research, launching a national education campaign to improve symptom recognition, setting research priorities for causes, biomarkers, and early detection, and reducing barriers to clinical trials for young adults. Additionally, it aims to address the specific needs of young patients and caregivers, including fertility, mental health, and work-related challenges, and establish an online federal resource hub. The Colorectal Cancer Alliance is actively rallying support for this legislation, emphasizing the urgent need for a nat...

Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Rockefeller University Scientists Discover Gut Antibodies Protect Against Colon Cancer by Regulating Cell Division

Scientists at Rockefeller University have discovered that immunoglobulin A (IgA) antibodies in the gut play a crucial role in preventing colon cancer. Their research, published in Nature, found that mice lacking IgA developed more than twice the usual number of colon tumors. The study elucidated that IgA antibodies bind to cells lining the gut, specifically epithelial cells, and prevent them from dividing too rapidly. This uncontrolled cell division is a precursor to cancer. Senior author Daniel Mucida, head of Rockefeller's Laboratory of Mucosal Immunology, highlighted that this finding reveals a natural defense mechanism that restrains cell division before tumors can form. The research also showed that administering oral doses of IgA to IgA-deficient mice eliminated their increased risk of developing tumors.

Aravax Announces Positive Phase 2 Trial Results for Peanut Allergy Immunotherapy PVX108 in US and Australia

Aravax Announces Positive Phase 2 Trial Results for Peanut Allergy Immunotherapy PVX108 in US and Australia

Aravax, a clinical-stage biotechnology company, has announced positive topline results from its Phase 2 clinical trial of PVX108, a novel immunotherapy for peanut allergy. The trial, conducted across 14 sites in the US and Australia, involved children aged 4 to 11 years. PVX108 is designed to retrain the immune system to tolerate peanuts while minimizing acute allergic reactions. The study met its primary efficacy endpoint, showing a statistically significant increase in the maximum tolerated dose of peanut in participants treated with PVX108 compared to placebo. Additionally, a significant reduction in the severity of food challenge reactions and an improvement in the emotional impact of living with a food allergy were observed. The treatment was well-tolerated, with no treatment-related allergic adverse events or serious adverse events reported. These results will be presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, AZ.